Patients with primary biliary cholangitis treated with obeticholic acid as second-line therapy within the POISE clinical trial had fewer deaths and liver transplants and experienced less hepatic decompensation than people treated in real-world settings, according to an analysis presented at the 2022 International Liver Congress.
Acknowledging the limitations of comparing carefully selected clinical trial patients to a more heterogeneous real-world population, investigator Gideon Hirschfield, MA,